Entera Bio Ltd. ENTXW 深 沪
等待开盘 02-11 09:30:00 美东时间
0.0012
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0012
- 总市值 2.85万
- 52周最高 0.328
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 2373.86万
- 历史最高 1.90
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Geno J. Germano
Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Geno J. Germano Entera Bio Ltd. has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commission. The filing names Geno J. Germano as a director of the company. The full filin
02-09 21:50
Entera Bio ernennt Ex-Pfizer-Manager Geno J. Germano zum neuen Aufsichtsratsvorsitzenden
Entera Bio ernennt Ex-Pfizer-Manager Geno J. Germano zum neuen Aufsichtsratsvorsitzenden Entera Bio Ltd. hat die Ernennung von Geno J. Germano, einem ehemaligen Führungskraft von Pfizer, zum neuen Chairman of the Board bekanntgegeben. Germano übernimmt die Position von Gerald Lieberman. Disclaimer:
02-09 21:46
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
Entera Bio Ltd. has appointed Geno J. Germano as its new Chairman, succeeding Gerald Lieberman. Germano, with over three decades of leadership experience in the biopharmaceutical industry, including senior roles at Pfizer and Wyeth, will guide Entera during a pivotal phase as the company advances two oral peptide programs into clinical trials in 2026: a Phase 3 study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in...
02-09 13:50
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Entera Bio Ltd. announced its key milestones for Q1 2026, including submitting the final Phase 3 protocol for EB613 to the FDA, expecting results from the Next-Generation EB613 Phase 1 bridging study, accelerating its hypoparathyroidism program with long-acting PTH variants, and advancing strategic partnerships across its pipeline. The Company remains committed to addressing unmet medical needs in osteoporosis and hypoparathyroidism.
01-21 13:30
Entera Bio Announces New Validating In Vivo Pharmacokinetic And Pharmacodynamic Data That Supports Development Of Proprietary Long-Acting PTH Analog Using N-Tab Platform For Patients With Hypoparathyroidism
Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides and proteins replacement therapies, today announced new validating in vivo pharmacokinetic and pharmacodynamic data
2025-12-22 21:33
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Entera Bio announced preclinical success in developing a novel, long-acting PTH analog using its N-Tab® platform. The analog achieved sustained calcium elevation for over three days with a single oral dose, addressing the need for a once-daily tablet alternative to daily injections for hypoparathyroidism patients. The study showed significantly longer plasma half-life and no adverse events, marking a potential breakthrough in treatment convenienc...
2025-12-22 13:30
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
2025年第三季度，Entera Bio宣布其骨质疏松治疗药物EB613获得FDA同意，将BMD作为注册性III期研究的主要终点。EB613的II期数据显示，该药物可显著提升 trabecular 和 cortical 骨指标，且在年轻绝经后女性中展现出一致疗效。此外，EB613下一代产品预计于2025年底启动I期试验。公司还展示了GLP-2在短 bowel综合征和OXM在肥胖症中的积极前临床数据。财务方面，截至9月底，公司现金及现金等价物为1660万美元，净亏损320万美元。
2025-11-14 21:05
Entera Bio Releases New Phase 2 Data At NAMS 2025 Showing That EB613, An Oral PTH[1-34] Therapy, Consistently Increased Bone Mineral Density In Both Early Postmenopausal Women And Those 10 Years Post-Menopause
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopauseData further support EB613 potential as a first-in-class oral anabolic
2025-10-23 20:58
Entera Bio Announces It Will Present New Phase 2 Clinical Data For EB613 At The North American Menopause Society 2025 Annual Meeting, October 21–25, 2025, In Orlando, Florida.
Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of EB613 at the upcoming North
2025-10-16 20:47
Entera Bio Presents Preclinical Data For OPK-8801003, Oral GLP-2 Tablet With Longer Half-Life Aiming To Replace Daily Injections For Short Bowel Syndrome Patients
Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 TherapyOral GLP-2 Tablet Could Transform Treatment
2025-09-15 21:05
